LMB-2 to Treat Hairy Cell Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 2, 2006

Primary Completion Date

August 24, 2016

Study Completion Date

December 31, 2022

Conditions
Hairy Cell Leukemia
Interventions
DRUG

Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin

LMB-2 Infusion: 40 micro-g/Kg will be infused in 50 ml of 0.9% Sodium Chloride (NaCl) and 0.2% albumin via over 30 minutes every other day for 3 doses. Patients may receive up to six treatment cycles every 4 weeks.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00321555 - LMB-2 to Treat Hairy Cell Leukemia | Biotech Hunter | Biotech Hunter